Analysis Of The Relationship Of Covid-19 Symptoms Which Receive Favipiravir And Length Of Treatment In The Inpatition Of Dr. Iskak Tulungagung

Aghnia Fuadatul Inayah (Pharmacist Professional Program, Faculty of Health Sciences, University of Muhammadiyah Malang)
Ghassani Shabrina Putri (Pharmacist Professional Program, Faculty of Health Sciences, University of Muhammadiyah Malang, Indonesia)
Amaliyah Dina Anggraeni (Pharmacist Professional Program, Faculty of Health Sciences, University of Muhammadiyah Malang, Indonesia)

Eduvest - Journal of Universal Studies
Vol. 4 No. 5 (2024): Journal Eduvest - Journal of Universal Studies

Coronavirus disease 2019 or commonly called COVID-19 is an infectious disease caused by SARS-CoV-2. Favipiravir is a broad-spectrum antiviral drug so it has potential antiviral action against SARS-CoV-2 which is an RNA virus. This research aims to find out the relationship between Covid-19 symptoms when receiving favipiravir and the length of treatment of patients hospitalized at RSUD Dr. Iskak Tulungagung. Observational research with descriptive retrospective methods in COVID-19 patients' moderate symptoms with Favipiravir therapy at RSUD dr. Iskak Tungagung period July - September 2021. Data collection using the calculation of the Slovin formula to determine the number of patient samples. Analysis analysis using SPSS by carrying out the Chi-square test. The results of the study were obtained from 146 patients, the pattern of using Favipiravir was given at a dose (2x1600mg) on the first day followed by (2x600mg) on the second day and so on with the most giving range of 1-7 days .